Barclays PLC Acquires 16,723 Shares of PepGen Inc. (NASDAQ:PEPG)

Barclays PLC boosted its holdings in shares of PepGen Inc. (NASDAQ:PEPG) by 318.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,971 shares of the company’s stock after acquiring an additional 16,723 shares during the period. Barclays PLC’s holdings in PepGen were worth $189,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PEPG. Point72 DIFC Ltd bought a new position in PepGen during the second quarter worth about $42,000. Allspring Global Investments Holdings LLC bought a new position in PepGen during the third quarter worth about $95,000. XTX Topco Ltd bought a new position in PepGen during the third quarter worth about $130,000. Renaissance Technologies LLC bought a new position in PepGen during the second quarter worth about $192,000. Finally, Marshall Wace LLP bought a new stake in shares of PepGen in the second quarter valued at about $196,000. 58.01% of the stock is currently owned by institutional investors.

PepGen Stock Performance

NASDAQ:PEPG opened at $2.08 on Wednesday. The stock’s 50-day simple moving average is $4.18 and its 200 day simple moving average is $8.12. The company has a market cap of $67.81 million, a P/E ratio of -0.70 and a beta of 1.66. PepGen Inc. has a 52-week low of $2.07 and a 52-week high of $19.30.

PepGen (NASDAQ:PEPG) last released its earnings results on Thursday, November 7th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.21. As a group, equities analysts predict that PepGen Inc. will post -2.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PEPG. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of PepGen in a report on Friday, November 8th. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target on the stock. in a report on Monday, December 16th. Finally, Wedbush cut their price target on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, November 8th.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.